Sign in to continue:

Sunday, March 1st, 2026

Zhong An Intelligent Completes HK$38.09 Million Share Placement and Discloseable Transaction Under General Mandate





Zhong An Intelligent Living Service Limited – Placing Completion and Shareholding Update

Zhong An Intelligent Living Service Limited and Zhong An Group Limited: Completion of Placing of New Shares and Deemed Disposal

Key Highlights

  • Successful Placing of New Shares: Zhong An Intelligent Living Service Limited (“Zhong An Intelligent”, Stock Code: 2271) has completed the placing of 25,450,000 new shares under the general mandate, with all conditions precedent fulfilled. The placement was executed through a placing agent to not less than six independent placees at HK\$1.52 per share.
  • Capital Raised: The net proceeds from the placement amount to approximately HK\$38.09 million after deducting all commissions and related expenses.
  • Use of Proceeds: The capital will be allocated equally (25% each) towards:
    • Settling staff costs and material costs (by end of 2026)
    • Settling subcontracting and supplier expenses (by end of 2026)
    • Office facilities and software upgrades (by end of 2027)
    • Application of artificial intelligence (AI) technologies (by end of 2027)
  • Impact on Shareholding Structure: The placing shares represent approximately 4.69% of the enlarged issued share capital of Zhong An Intelligent. The shareholding of Zhong An Service Holding Limited (a wholly-owned subsidiary of Zhong An Group Limited) was diluted from 71.28% to 67.94%.
  • Deemed Disposal: As a result of the placing, Zhong An Group Limited’s indirect interest in Zhong An Intelligent decreased by approximately 3.34%. However, Zhong An Intelligent remains an indirect non-wholly owned subsidiary, and its financial results will continue to be consolidated into Zhong An Group’s financial statements.

Details for Investors and Shareholders

Background on the Placing

The placing was conducted under the general mandate as approved at Zhong An Intelligent’s general meeting. The shares were placed to at least six independent third-party investors, ensuring no new substantial shareholder was created as defined under the Listing Rules. This indicates broad-based investor confidence and no resultant change in control.

Financial Impact and Use of Funds

Net proceeds of approximately HK\$38.09 million will be strategically deployed to enhance operational efficiency and technological capabilities. The breakdown is as follows:

  • 25% for staff and material costs, supporting core operations and workforce stability through end-2026.
  • 25% for settling subcontracting and supplier expenses, ensuring supply chain reliability and vendor relationships through end-2026.
  • 25% for upgrading office facilities and software, enhancing operational infrastructure by end-2027.
  • 25% for AI technology application, signaling a move towards digital transformation and potential innovations by end-2027.

These investments may improve the company’s competitiveness, efficiency, and technological edge, potentially leading to higher profitability and market valuation in the medium to long term.

Shareholding Structure Changes

Shareholder Before Placing After Placing
Zhong An Service Holding Limited 368,796,000 shares (71.28%) 368,796,000 shares (67.94%)
Other Shareholders 148,618,000 shares (28.72%) 148,618,000 shares (27.37%)
Placees 25,450,000 shares (4.69%)
Total 517,414,000 shares 542,864,000 shares

Corporate Governance and Board Composition

The boards of both Zhong An Intelligent and Zhong An Group remain unchanged, with Shi Zhongan serving as Chairman for both entities. Executive, non-executive, and independent non-executive directors are listed, underscoring continuity in governance.

Potential Share Price Impact and Considerations

  • Share Dilution: While the placing results in a dilution of existing shareholders, the broad base of new placees and no emergence of a new substantial shareholder limits risks of control shifts or governance changes.
  • Strategic Use of Proceeds: The allocation of proceeds towards operational and technological improvements could enhance long-term shareholder value.
  • Improved Liquidity: The increased number of shares in circulation may improve liquidity and market depth.
  • Continuation as a Consolidated Subsidiary: Zhong An Intelligent remains a core part of Zhong An Group, reassuring investors about management stability and continued strategic alignment.

Conclusion

This placing transaction is significant for both Zhong An Intelligent and Zhong An Group shareholders. It reflects strong investor demand, supports the company’s transformation and growth agenda, and maintains group control, all of which could have positive implications for share value and investor confidence.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult their financial advisors before making any investment decisions. The information is based on the latest available public disclosures as of 27 February 2026. No responsibility is taken for any losses arising from reliance on this article.




View ZHONGAN SERVICE Historical chart here



Town Ray Holdings Issues Profit Warning for FY2025: Expected Net Profit Drops by Up to 47% Due to Rising Costs and Product Strategy 12

Town Ray Holdings Limited Issues Significant Profit Warning Town Ray Holdings Limited Issues Significant Profit Warning for FY2025 Key Points from the Announcement Profit Decline Expected: Town Ray Holdings Limited (Stock Code: 1692) has...

Public Disclosure of UBS AG Share Dealings in ENN Energy Holdings Limited (February 2026)

UBS AG Discloses Dealings in ENN Energy Holdings Shares Amid Privatisation Scheme UBS AG Discloses Significant Trading Activity in ENN Energy Holdings Shares Date: 26 February 2026 Subject: Public Disclosure of Share Dealings in...

Shanghai Henlius Biotech Doses First Patient in Phase 2/3 Clinical Trial of HLX22 and HLX87 for HER2-Positive Breast Cancer in China 123

Shanghai Henlius Biotech Doses First Patient in Pivotal Phase 2/3 Breast Cancer Study — Key Developments for Investors Shanghai Henlius Biotech Initiates Phase 2/3 Clinical Study for HLX22 and HLX87 in HER2-Positive Breast Cancer...

   Ad